Gold prices bounce off 3-week lows; demand likely longer term
WALTHAM, Mass. - Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS), a company specializing in robotic surgery technology with a current market capitalization of $54.24 million, announced the appointment of Sarah Romano as its new Chief Financial Officer, effective April 1, 2025. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics, though it faces significant challenges with rapid cash burn. Romano is tasked with steering the financial strategy of the firm, drawing on her extensive experience in the healthcare sector, particularly with public companies where she has led successful fundraising and mergers and acquisitions.
Romano’s career includes a recent role as CFO of Entero Therapeutics, where she managed financial strategy and operations. At Kiora Pharmaceuticals, she secured over $50 million in funding and led M&A activities. Her background also includes positions of increasing responsibility in financial forecasting, internal controls, and SEC reporting. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.
Adam Sachs, Co-Founder and CEO of Vicarious Surgical, expressed confidence in Romano’s abilities to advance the company’s financial goals and contribute to its success. Romano herself is eager to leverage her expertise as the company approaches its first clinical use cases later this year. With the company’s next earnings report due in 4 days, InvestingPro subscribers can access 10+ additional exclusive insights and detailed financial analysis about RBOT’s performance and outlook.
Vicarious Surgical, founded in 2014 and based in Waltham, Massachusetts, aims to transform the efficiency, outcomes, and costs associated with surgery through its proprietary surgical robots. The company’s technology is designed to offer a minimally invasive approach, virtually transporting surgeons inside the patient. While the stock has seen a significant 57.73% gain over the past six months, it remains down 30.24% year-to-date. Vicarious Surgical enjoys backing from notable investors such as Bill Gates and Vinod Khosla’s Khosla Ventures.
This announcement is based on a press release statement from Vicarious Surgical Inc. and includes forward-looking statements subject to risks and uncertainties. The company’s actual results may differ from current expectations and projections. Factors influencing these outcomes include market conditions, regulatory approvals, competition, and other risks detailed in the company’s SEC filings.
In other recent news, Vicarious Surgical Inc. announced the upcoming retirement of its Chief Operating Officer, John Mazzola, set for April 2025. Randy Clark, currently the company’s President, will succeed Mazzola, who has been instrumental in enhancing manufacturing processes and supply chain management. Additionally, Vicarious Surgical has entered into a consulting agreement with its former Chief Financial Officer, William Kelly, who will provide advisory services to the company until the end of 2028. This agreement allows Mr. Kelly to retain vesting rights to his stock options and includes clauses on confidentiality and non-solicitation. The company is leveraging Mr. Kelly’s expertise during the transition to a new CFO. These developments are part of Vicarious Surgical’s strategic efforts as it continues to progress in the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.